ICLE 2022 | Improving the efficiency of cancer vaccines with adoptive T cell therapy approaches

Chiara Bonini, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Institute, Milan, Italy, explains how the development and success of adoptive T cell therapies has helped evolve the landscape of personalized therapeutic cancer vaccine development. Early cancer vaccines had low efficiencies and were only able to elicit therapeutic responses in a small number of patients, however, it is now believed that combining tumor vaccination with other therapies targeting immunosuppressive pathways such as adoptive T cell therapy could significantly enhance their clinical potential. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.